Feature | Artificial Intelligence | October 22, 2018 | By Greg Freiherr

WEB EXCLUSIVE: Smart Machines To Empower Oncology Docs and Patients, Say ASTRO Experts

This is the second web exclusive article in a series from Consulting Editor Greg Freiherr, reporting live from the show floor at ASTRO 2018

Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them better at the jobs only they can do, said speakers at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas.

Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them better at the jobs only they can do, said speakers at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas.

“AI is going to do the things that a machine can do better, and by offloading tasks (from people), it will enable us to do the more exciting stuff that we really need people for,” said Kristy K. Brock, Ph.D., a professor of imaging physics at The University of Texas MD Anderson Cancer Center in Houston. “We will be able to do the interpretations and (what) drives science forward — rather than checking the numbers that you would put into the computer.”

Machines cannot satisfy the inherently human function of physicians in health care; they cannot interact adequately with patients, said Andre Dekker, Ph.D., who followed Brock on stage at the ASTRO symposium. But artificial intelligence can provide the tools that will make this interaction more beneficial, he told a standing-room-only crowd of hundreds who attended the talks about AI.

“AI will allow us to share decision-making,” said Dekker, medical physicist and head of knowledge engineering at the MAASTRO clinic and professor at Maastricht University in Maastricht, The Netherlands. “We will be able to ask: ‘If treatments A to Z have these predicted outcomes, what fits you best? Is the toxicity worth it? Is the benefit worth it?’ ”

Consumer acceptance of AI is paving the way for this technology to have an increasingly important impact on the practice of medicine, Brock said.  AI is part of the public’s collective imagination from Amazon.com’s Alexa responding to requests from consumers to order more detergent to a predicted future of driverless cars.

In radiation oncology, artificial intelligence will be an enabling technology, she predicted, “not a robot-replacing-human technology.” It will enable radiation oncologists to generate the optimal patient information for the lowest risk in imaging, as well as intervention, Brock said.  It will allow the tumor burden to be accurately identified; the risk to be stratified; and the treatment to be planned.

 

First Impact

The availability of data used to train and validate smart algorithms will be an important limiting factor, however, in when and how AI will be applied in radiation oncology, Dekker said. Its availability will depend on overcoming barriers to sharing data, he said. Several factors may result in these barriers.

One is rooted in human nature.  People simply may not want to share the data they have gathered, he said. Or they may lack the resources to share the data. Or they may be prevented from sharing data by language differences. 

But, just as AI applications require the availability of data, so might AI fuel the applications to overcome these barriers. Such applications might automate the “mining” of clinical data, thereby reducing the time and cost of gathering data, just as they might translate data from one language to another, Dekker said.

 

Empowering Patients

Big data, crunched by smart algorithms, may eventually paint scenarios of how patients will fare with different treatment options, he said. In the future, he opined, smart machines might calculate the odds that different treatment options will have certain effects and toxicities; physicians might explain those options; and patients might choose which is best for them.  One treatment, for example, might offer longer survival, but be accompanied by the risk of greater toxicity and complications. Another might come with shorter survival, but less risk of toxicity and complications.  

“Will AI in the future allow us to precisely determine what will be the best treatment with the lowest toxicity and to understand these risks and benefits?” Brock asked. “Will we be able to translate this plan to the best plan that can be delivered?”

The optimization of patient outcomes will result, if AI is applied to improve processes in radiation oncology, according to Dekker. This will happen because the improvement of processes necessarily improves patient outcomes.

Ultimately AI will be a winning proposition for both patients and physicians. “You will have this ‘citizen science component,’” he said.  “It won’t mean that doctors are not necessary anymore.” 

 

For additional ASTRO information, see “WEB EXCLUSIVE: Market for MRI-based RT Could Soon Widen.”

Related Content

Videos | Radiation Oncology | September 20, 2019
Anne Hubbard, MBA, director of health policy for ASTRO, explains the details and purpose of the proposed Radiation On
Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...
Videos | Radiation Therapy | September 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with...
Aktina Showcases New Radiotherapy Patient Immobilization Solutions at ASTRO 2019
News | Patient Positioning Radiation Therapy | September 20, 2019
Aktina Medical introduced several new products at the 2019 American Society for Radiation Oncology (ASTRO) annual...
Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System
News | Proton Therapy | September 20, 2019
Varian announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360...
Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology

Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology (ASTRO), explains the details of the proposed radiation oncology alternative payment model (APM), and issues ASTRO has raised with the model, at the 2019 ASTRO annual meeting in Chicago.

News | Radiation Oncology | September 18, 2019
During its annual meeting in September, the American Society for Radiation Oncology (ASTRO) issued a response to the...
Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
IBA Gathers Experts on Flash Irradiation During ASTRO
News | Proton Therapy | September 17, 2019
IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019...
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

The PlanCheck module now part of SunCheck, automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent.

News | Quality Assurance (QA) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, running Sept. 15-18 in Chicago, Sun Nuclear...